J Woody Sistrunk1, Alexander Shifrin2, Marc Frager3, Ricardo H Bardales4, Johnson Thomas5, Norman Fishman6, Philip Goldberg7, Richard Guttler8, Edward Grant9. 1. Jackson Thyroid & Endocrine Clinic, Jackson, Mississippi. Electronic address: woodysistrunk@gmail.com. 2. Department of Surgery, Hackensack Meridian Health Jersey Shore University Medical Center, Neptune, New Jersey. 3. East Coast Medical Associates, Boca Raton, Florida. 4. Precision Pathology/Outpatient Pathology Associates, Sacramento, California. 5. Mercy Clinic Endocrinology, Springfield, Missouri. 6. Diabetes & Endocrinology Specialists, Chesterfield, Missouri. 7. Endocrine Associates of Connecticut, Branford, Connecticut. 8. Thyroid Center of Santa Monica, Santa Monica, California. 9. Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
INTRODUCTION: We evaluated the clinical performance of an expanded mutation panel in combination with microRNA classification (MPTX) for the management of indeterminate thyroid nodules. MATERIALS AND METHODS: MPTX included testing of fine-needle aspirates from multiple centers with a combination of ThyGeNEXT mutation panel for strong and weak driver oncogenic changes and ThyraMIR microRNA risk classifier (both from Interpace Diagnostics; Pittsburgh, PA). MPTX test status (positive or negative) and MPTX clinical risk classifications (low, moderate, or high risk) were determined blind to patient outcomes. Surgical pathology and clinical follow-up records of patients from multiple centers were used to determine patient outcomes. MPTX performance was assessed by Kaplan Meier analysis for cancer-free survival of patients, with risk of malignancy determined by hazard ratio (HR). RESULTS: Our study included 140 patients with AUS/FLUS or FN/SFN nodules, of which 13% had malignancy. MPTX negative test status and MPTX low risk results conferred a high probability (94%) that patients would remain cancer-free. MPTX positive test status (HR 11.2, P < 0.001) and MPTX moderate-risk results (HR 8.5, P = 0.001) were significant risk factors for malignancy, each conferring a 53% probability of malignancy. MPTX high-risk results elevated risk of malignancy even more so, conferring a 70% probability of malignancy (HR 38.5, P < 0.001). CONCLUSIONS: MPTX test status accurately stratifies patients for risk of malignancy. Further classification using MPTX clinical risk categories enhances utility by accurately identifying patients at low, moderate, or high risk of malignancy at the low rate of malignancy encountered when clinically managing patients with indeterminate thyroid nodules.
INTRODUCTION: We evaluated the clinical performance of an expanded mutation panel in combination with microRNA classification (MPTX) for the management of indeterminate thyroid nodules. MATERIALS AND METHODS:MPTX included testing of fine-needle aspirates from multiple centers with a combination of ThyGeNEXT mutation panel for strong and weak driver oncogenic changes and ThyraMIR microRNA risk classifier (both from Interpace Diagnostics; Pittsburgh, PA). MPTX test status (positive or negative) and MPTX clinical risk classifications (low, moderate, or high risk) were determined blind to patient outcomes. Surgical pathology and clinical follow-up records of patients from multiple centers were used to determine patient outcomes. MPTX performance was assessed by Kaplan Meier analysis for cancer-free survival of patients, with risk of malignancy determined by hazard ratio (HR). RESULTS: Our study included 140 patients with AUS/FLUS or FN/SFN nodules, of which 13% had malignancy. MPTX negative test status and MPTX low risk results conferred a high probability (94%) that patients would remain cancer-free. MPTX positive test status (HR 11.2, P < 0.001) and MPTX moderate-risk results (HR 8.5, P = 0.001) were significant risk factors for malignancy, each conferring a 53% probability of malignancy. MPTX high-risk results elevated risk of malignancy even more so, conferring a 70% probability of malignancy (HR 38.5, P < 0.001). CONCLUSIONS:MPTX test status accurately stratifies patients for risk of malignancy. Further classification using MPTX clinical risk categories enhances utility by accurately identifying patients at low, moderate, or high risk of malignancy at the low rate of malignancy encountered when clinically managing patients with indeterminate thyroid nodules.
Authors: Esther Diana Rossi; Pietro Locantore; Carmine Bruno; Marco Dell'Aquila; Pietro Tralongo; Mariangela Curatolo; Luca Revelli; Marco Raffaelli; Luigi Maria Larocca; Liron Pantanowitz; Alfredo Pontecorvi Journal: Front Endocrinol (Lausanne) Date: 2022-05-12 Impact factor: 6.055
Authors: Shahnawaz Imam; Rodis D Paparodis; Shafiya Imtiaz Rafiqi; Sophia Ali; Azra Niaz; Abed Kanzy; Yara E Tovar; Mohammed A Madkhali; Ahmed Elsherif; Feras Khogeer; Zeeshan A Zahid; Haider Sarwar; Tamanna Karim; Nancy Salim; Juan C Jaume Journal: Front Oncol Date: 2022-05-27 Impact factor: 5.738
Authors: Mark A Lupo; Ann E Walts; J Woody Sistrunk; Thomas J Giordano; Peter M Sadow; Nicole Massoll; Ryan Campbell; Sara A Jackson; Nicole Toney; Christina M Narick; Gyanendra Kumar; Alidad Mireskandari; Sydney D Finkelstein; Shikha Bose Journal: Diagn Cytopathol Date: 2020-08-07 Impact factor: 1.582